Avacincaptad pegol is the first investigational therapy in GA to achieve the 12-month prespecified, primary endpoint, in two pivotal, phase 3 studies
Benefit across subgroups seen in GATHER1 increases with duration of therapy
Prespecified subgroup analysis shows benefit of avacincaptad pegol in all prespecified subgroups
Primary endpoint achieved at year one with a high degree of statistical significance
https://investors.ivericbio.com/static-files/8e84c2f5-1e03-444a-bf27-8081e441a1b7
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.